Unmethylated MGMT Gene Promoter clinical trials at UC Health
1 research study open to new patients
open to eligible people ages 18 years and up
This phase 0/I trial studies the side effects and best dose of MDM2 inhibitor AMG-232 in treating patients with glioblastoma that is newly diagnosed or has come back. MDM2 inhibitor AMG-232 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.